New Zealand's advanced bioactive nutrition platform — from native honey to precision nutraceuticals, sports nutrition, and clinical-grade ingredient systems.
We take New Zealand's most bioactively complex native honeys and convert them into validated, multi-application nutrition systems — sold as CPG consumer products, licensed as B2B ingredient systems, and deployed as a proprietary bioactive intelligence platform. Māori-led, science-backed, globally positioned.
Mānuka Performance is New Zealand's advanced bioactive nutrition company — converting the world's most scientifically validated native honey into a global multi-channel nutrition platform.
Mānuka Performance Limited (MPL) is a New Zealand Māori-led company that develops, manufactures, and commercialises precision nutrition systems built on a proprietary bioactive platform — PolySure™ — derived from New Zealand's native Mānuka and Rewarewa honey. We are not a honey company. We are an advanced nutrition manufacturing and export company that uses honey as the world's most complex and defensible bioactive matrix.
Every MPL product is built on PolySure™ — our proprietary bioactive certification system that tracks seven distinct polyphenols per batch, verified to ISO-17025 (IANZ/ILAC-MRA accredited laboratory), with a Certificate of Analysis issued on every production run. No competitor can replicate this. NZ native honey varieties are geographically protected, genetically unique, and subject to our exclusive sourcing relationships. PolySure™ is the structural moat across all four commercial pillars.
MPL operates from an Auckland GMP-compliant manufacturing base with Informed Sport certification, FDA GRAS-status probiotic integration (BC30™), and New Zealand FernMark licensing. Products are designed for multi-channel commercial deployment: direct-to-consumer (D2C), Amazon, telehealth B2B, HCP networks, corporate wellness, and cross-border e-commerce (CBEC China). The science platform is additionally licensable as a B2B ingredient system and data intelligence asset.
Māori guardianship over IP and cultural assets is structurally enshrined — not aspirational language. Our US commercialisation is led by Dr Marc Stevens MD (CMO and US Co-President), a physician with deep telehealth and clinical nutrition networks. Our science is led by Dr Lillian Morton PhD (CSO). This combination — Māori-led IP sovereignty, physician clinical credibility, and export manufacturing capability — is not replicable by any competitor in our category.
One raw material. Three tiers of engineered value — from certified bioactive formulations through to clinical-grade licensed IP. This is where the honey industry stops. This is where we start. Raw honey is our origin, not our product.
Mānuka and Rewarewa honey from New Zealand's indigenous flora. Geographically irreplaceable. Genetically unique. The only honey in the world with a validated 7-polyphenol bioactive profile verifiable to ISO-17025 laboratory standards. This is the raw input that no competitor can access or replicate.
Six addressable customer and channel segments — across consumer, clinical, B2B, and institutional channels in five markets. Realistic market sizing with defensible assumptions.
USD$5 million growth round to accelerate what is already working — live sales in the USA and South Korea, a completed product stack, and a defensible science platform no competitor can replicate.
This is a growth round — not a startup round. MPL has live commercial traction in two export markets (USA and South Korea), Auckland manufacturing on a clear GMP pathway, an active RCT, and a completed four-SKU product stack. Capital introduced now will scale what is already working, not fund product discovery. The window to establish first-mover positioning in GLP-1 companion nutrition and NZ bioactive ingredients globally is open now — and will not be open in 36 months.
South Korea has one of the highest rates of marathon and long-distance running participation on the planet — approximately 620,000 annual marathon finishers, with a deeply embedded culture of endurance sport, clean nutrition, and premium product. LiquidFuel™ is live in this market, generating revenue now. The channel is established. The product is proven. Capital accelerates what already works.
The pipeline for South Korea expands into GI-PRO™ gut health and nutraceutical supplements through the same endurance and active wellness channel — a customer base that indexes extremely high on science-backed, premium-format, provenance-led nutrition.
China's cross-border e-commerce health and supplement market exceeds $12B. NZ-origin gut health products command a significant provenance premium — Chinese consumers actively seek authentic NZ science-backed nutrition. GI-PRO™ is the designed CBEC launch SKU: compact, daily-use sachet format, NZ FernMark provenance, clinically grounded. Platforms: Tmall Global, JD Worldwide, WeChat Health.
China's 12,000+ active CBEC operators and contract nutraceutical manufacturers represent a significant B2B ingredient opportunity. MPL supplies PolySure™-certified bioactive honey formulations — not commodity ingredients — to supplement brands, functional food manufacturers, and food service operators requiring independently verified NZ-origin bioactive systems. Each B2B contract generates volume revenue and validates the science platform for licensing conversations.
| Metric | Year 1 | Year 2 | Year 3 |
|---|---|---|---|
| USA Total Revenue | $484K | $1.93M | $3.29M |
| → D2C | — | — | $1.48M |
| → Amazon | — | — | $1.11M |
| → Telehealth B2B | — | — | $544K |
| South Korea Revenue | $48K | $140K | $280K |
| → LiquidFuel™ Endurance (live) | $48K | $95K | $160K |
| → GI-PRO™ + Nutraceutical Pipeline | — | $45K | $120K |
| China Revenue | $105K | $340K | $800K |
| → GI-PRO™ CBEC Consumer | $45K | $160K | $320K |
| → B2B Ingredient & Food Service | $60K | $180K | $480K |
| COMBINED TOTAL REVENUE | $637K | $2.41M | $4.37M |
| Blended Gross Margin | 60% | 60% | 60% |
| EBITDA (consolidated) | ($190K) | $360K | $890K |
| EBITDA Positive | No | Yes — Y2 | Consolidating |
| Bridge Round Required | None — single USD$5M round finances to profitability across all markets | ||
The GLP-1 nutrition companion category will be structurally defined within 18–24 months. The first mover with physician credibility, telehealth B2B distribution, and a defensible science platform will own the category. Mānuka Performance is that company. Capital introduced now captures the full upside of that positioning.